Method of treating chronic elbow and prepatellar brusitis

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to traumatology-orthopedics and surgery, and can be applied for treatment of chronic elbow and prepatellar brusitis. For this purpose puncture of bursa, its content aspiration, introduction of medication in its cavity, drainage of bursa with constant active aspiration are realised. As medication 2 ml of heparin 10000 IU are introduced in bursa cavity. After 24 hours aspiration of content is carried out and 2 ml of heparin 10000 IU and 10 mg of trypsin are introduced. 3 hours after this vacuum system of active aspiration is placed in bursa cavity. Further, in a day removal of aspiration liquid from system is realised in the process of bandaging. System of active aspiration is applied until exudate extraction from bursa stops.

EFFECT: method ensures improvement of treatment effects as a result of reduction of pain reaction to medicinal procedure, reduction of quantity of recurrences as a result of active influence on synovial envelope of bursa, thorough evacuation of its content and activation of regeneration processes.

1 dwg, 2 ex

 



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a pharmaceutical composition for control of pain accompanying individual's joint diseases containing hyaluronic acid, which is cross-linked by cycling a double bond in a group of cinnamic acid in partially amidated hyaluronic acid presented by formula (1) to form a cyclobutane cycle, wherein in the above formula, Ar represents a phenyl group, n is equal to an integer 2 or 3; HA represents a carboxy residue of hyaluronic acid, and m represents a relation of amidation of hyaluronic acid to all the carboxyl groups and is equal to 3-50% in relation to all the carboxyl groups, and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition represents a product for injection, wherein the pharmaceutical composition represents the product for injection, wherein the amount of the cross-linked hyaluronic acid makes 1 wt % at the total amount of the product for injection, wherein a single dose of the product for injection makes 2-3 ml, wherein the pharmaceutical composition represents a single-use preparation, which is administered every 13 weeks and more.

EFFECT: invention provides the extremely long analgesic action after the single administration, earlier onset of the analgesic action.

15 cl, 1 dwg, 5 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to pharmaceutical compositions for the combined therapy of arthropathies, except for rheumatoid arthritis, degenerative disk diseases, joint pains and/or autoimmune disease (particularly alopecia, neurodermitis). There are presented: a pharmaceutical composition for the above application containing a glucocorticoid, exosomes prepared of autologous blood and a cytokine antagonist ortokin or anakinra; a method for producing it involving the pharmaceutical composition containing the exosomes prepared of autologous blood and the cytokine antagonist ortokin or anakinra, and the pharmaceutical composition containing the glucocorticoid and the cytokine antagonist ortokin or anakinra, and versions of using the above substances for producing the pharmaceutical composition for the combined therapy.

EFFECT: technical effect consists in achieving the synergetic effect both on the exposure rate and remote outcomes of the specified diseases with reducing side effects of the glucocorticoid (cortisone).

33 cl, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical composition, containing compound of formula or for prevention or treatment of diseases, associated with oxidative stress, selected from group, consisting of MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke episodes), MERRF syndrome (myoclonic epilepsy with ragged red fibres) or Kearns-Sayre syndrome, arrhythmia, cardioplegia or myocardium infarction. in formula (1) na stands for 1 or 2, Aa represents 5-membered heteroaryl or heterocycle, each of which has 2 heteroatoms, selected from N, O and S, Rla represents R5a-Xa-Ba-X′a-, Ba represents direct bond, Xa and X′a independently on each other represent direct bond or -OC(O)-, R5a represents hydrogen or 6-9-membered monocyclic or condensed cyclic heterocycle or heteroaryl, each of which has from 1 to 3 heteroatoms, selected from N, O and S, and is optionally substituted with oxo or C1-C6-alkyl, R2a represents -(CR8aR9a)pa-Ya-R7a, pa stands for number from 0 or 1, Ya represents direct bond or -O-, R7a represents hydrogen or phenyl, R3a, R8a, R9a, R10a represent hydrogen, R4a represents -(CH2)pa-Da-R10a-, Da represents C5-cycloalkyl or 6-membered heterocycle, which has 1 heteroatom, selected from N, S and O. Radical values for formula (2) are give in invention formula.

EFFECT: obtaining compositions for prevention or treatment of diseases, associated with oxidative stress.

19 dwg, 5 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to rheumatology, and can be used in treating patients suffering from rheumatoid arthritis. The method involves prescribing methotrexat 15 mg a week per os, folic acid 5 mg a week per os, movalis 15 mg a day per os. If the patient has the second degree of activity of rheumatoid arthritis, IL-1β of 1.3±0.3 pg/ml and more, IL-6 of 1.5±0.3 pg/ml and more, TNF-α of 1.78±0.35 pg/ml and more, IL-4 of 3.7±0.34 pg/ml and less, leptine of 6.4±0.42 pg/ml and more, glycosaminoglycans of 0.310±0.032 g/l, 7 daily procedures of intravenous laser exposure are prescribed. The KL-VLOK radiation head with a wavelength of 635 nm, disposable light guide tip power of 1.5 mW, exposure time of 15 minutes is alternated every second day with the KL-VLOK-365 laser head for UV blood exposure with a wavelength of 365 nm, light guide tip power of 1.0 mW and exposure time of 5 minutes. If observing the third degree of activity, IL-1β of 2.01±0.18 pg/ml and more, IL-6 of 3.01±0.38 pg/ml and more, TNF-α of 3.3±0.25 pg/ml and more, IL-4 of 1.3±0.24 pg/ml and less, leptine of 8.8±0.72 pg/ml and more, glycosaminoglycans of 1.3±0.54 g/l, 10 daily procedures are performed. The KL-VLOK radiation head with a wavelength of 635 nm, disposable light guide tip power of 1.5-2.0 mW, exposure time of 15 minutes is alternated every second day with the KL-VLOK-365 laser head for UV blood exposure with a wavelength of 365 nm, light guide tip power of 1.0 mW and exposure time of 5 minutes.

EFFECT: method enables reducing a rate of aggravations, an intensity of clinical manifestations, drug load on the patient, prolonging remissions ensured by a normalising effect on cytokine dynamics - reduced pro-inflammatory and increased anti-inflammatory cytokines.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to compound, represented by the following formula

,

or its pharmaceutically acceptable salt. In claimed formula each symbol has values, determined in formula of invention. Versions of formula [I] compound and particular compounds are also objects of invention. In addition, invention relates to pharmaceutical composition, ITK inhibitor and means for treatment or prevention of inflammatory diseases, allergic diseases, autoimmune diseases, transplant rejection and other diseases and methods of treating said diseases.

EFFECT: claimed compounds inhibit induced T-cellular kinase (ITK).

32 cl, 86 tbl, 387 ex

Treatment // 2554801

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, and concerns using a human Annexin-1 antibody (Anx-A1), which has the sequence SEQ ID NO: 23 for treating a disease caused by abnormal T-cell activation. The group of inventions also concerns a method of treating a disease caused by abnormal T-cell activation, involving administering a therapeutic amount of the above antibody into an individual in need thereof; using the above antibody for producing a therapeutic agent for treating a disease caused by abnormal T-cell activation.

EFFECT: group of inventions provides treating the disease caused by abnormal T-cell activation.

9 cl, 11 ex, 22 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a compound of formula , which is a methylhydrofumarate (MHF) prodrug. In formula (I), radicals and symbols have the values specified in the patent claim. The invention also refers to a pharmaceutical composition containing the declared methylhydrofumarate drugs, to using the declared methylhydrofumarate drugs and the pharmaceutical composition containing them, for treating diseases, such as psoriasis, asthma, multiple sclerosis, inflammatory intestinal disease and arthritis, and to a method of treating the above diseases.

EFFECT: higher oral bioavailability and plasma MHF, dimethylfumarate and/or other metabolites.

47 cl, 1 tbl, 54 ex

FIELD: medicine.

SUBSTANCE: as medications administered are: methotrexate 15 mg per week intake, folic acid 5 mg per week intake, movalis 15 mg per day intake. Laser therapy is administered in differential way depending on degree of disease activity and level of glucosaminoglycanes (GAG). In case of second stage of rheumatoid arthritis - index DAS28 3.2-5.1, level of glucosaminoglycanes 0.510±0.032 g/l, 7 daily procedures of intravenous laser irradiation are carried out. Radiating head KL-VLOK with wavelength 635 nm, power at the end of disposable light guide 1.5 mW, exposure time 15 minutes and laser head KL-VLOK-365 with wavelength 365 nm, power at the end of light guide 1.0 mW, exposure time 5 minutes, are alternated. In case of third degree of activity index DAS28 is higher than 5.1, GAG level is equal or is higher than 0.618±0.069 g/l, 10 procedures are carried out Radiating head KL-VLOK with wavelength 635 nm, power at outlet of disposable light guide 1.5-2.0 mW, exposure time 15 minutes and laser head KL-VLOK-365 nm, power at outlet of disposable light guide 1.0 mW, time of exposure 5 minutes.

EFFECT: method makes it possible to reduce frequency of exacerbations, reduce expression of clinical manifestations, reduce drug load on patient, provides earlier arrest of disease symptoms due to differentiated approach in case of administration of intravenous laser irradiation of blood and its normalising action on GAG indices and reduction of disease activity degree.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to novel N-containing heteroaryl derivatives of formula I or II or their pharmaceutically acceptable salts, which possess properties of JAK kinase, in particular JAK3, and can be applied for treating such diseases as asthma and chronic obstructive pulmonary disease (COPD). In formulae A represents carbon and B represents nitrogen or A represents nitrogen and B represents carbon; W represents CH or N; R1 and R2, independently represent hydrogen, C1-4alkyl, halogenC1-4alkyl, -CN; R3 represents C1-4alkyl, R9-C1-4alkyl, Cy1, where Cy1 is optionally substituted with one or several substituents R10; R4 represents hydrogen, C1-4alkyl, R12R7N-C0alkyl, where one of R7 and R12 represents hydrogen, and the other represents C1-4alkyl or group R13, which is selected from C1-5alkyl, Cy2-C0alkyl; R5 represents hydrogen; R6 represents hydrogen, C1-4alkyl, C1-4alkoxyC1-4alkyl, hydroxyC1-4alkyl, R12R7N-C1-4alkyl, R16CO-C0alkyl, Cy1; R7 represents hydrogen or C1-4alkyl; R9 represents halogen, -CN, -CONR7R12, -COR13, CO2R12, -OR12, -SO2R13, -SO2NR7R12, -NR7R12, -NR7COR12; R10 represents C1-4alkyl or R9-C0-4alkyl; R11 represents C1-4alkyl, halogen, -CN, -NR7R14; R12 represents hydrogen or R13; R13 represents C1-5alkyl, hydroxyC1-4alkyl, cyanoC1-4alkyl, Cy2-C0alkyl or R14R7N-C1-4alkyl; where Cy2 is optionally substituted with one or several constituents R11; R14 represents hydrogen or C1-4alkyl; R16 represents C1-4alkyl, halogenC1-4alkyl, C1-4alkoxyC1-4alkyl, hydroxyC1-4alkyl or cyanoC1-4alkyl; Cy1 represents monocyclic carbocyclic unsaturated or saturated ring, selected from C3-C6cycloalkyl, phenyl, or saturated monocyclic 4-6-membered heterocyclic ring, containing from 1 to 2 heteroatoms, selected from N and S, or partially unsaturated 10-membered bicyclic heterocyclic ring, containing oxygen atom as heteroatom, which can be substituted with group R11, where said ring is bound with the remaining part of molecule via any available C atom, and where one or several ring C or S atoms are optionally oxidised with formation of CO or SO2; and Cy2 represents monocyclic carbocyclic unsaturated ring, selected from C3-C6cycloalkyl, or aromatic monocyclic 4-6-membered heterocyclic ring, containing from 1 to 2 heteroatoms, selected from N and S, or unsaturated 10-membered bicyclic heterocyclic ring, containing oxygen atom as heteroatom, which can be substituted with group R11, where said ring is bound with the remaining part of molecule via any available atom C or N.

EFFECT: obtaining novel heteroaryl derivatives.

27 cl, 41 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: pharmaceutical composition in the form of a tablet with an erodible matrix, which contains one or more fumaric acid ethers, as well as a rate-controlling agent, representing hydroxypropylcellulose and a binding agent, representing lactose, with the decomposition of the said degradable matrix providing the controlled release of the said fumaric acid ether (ethers).

EFFECT: provision of the controlled release of fumaric acid ether (ethers).

19 cl, 43 ex, 2 tbl, 2 dwg

FIELD: medicine.

SUBSTANCE: catheter is inserted into the retrobulbar space and used to introduce 2% lidocaine 1 ml and 0.5% marcaine 1 ml 15-20 minutes before applicator anchoring. The catheter is left in the retrobulbar space for 1-7 days. 10-15 minutes before removing the applicator, 2% lidocaine 0.5-1 ml and 0.5% marcaine 0.5-1 ml are introduced through the catheter. 4-6 hours after anchoring and removing the applicator, 2% lidocaine 1 ml and 0.5% marcaine 1 ml are introduced respectively additionally.

EFFECT: achieving adequate and prolonged anaesthesia in a combination with reducing a risk of a retrobulbar haematoma, eyeball puncture and visual nerve damage by eliminating the retrobulbar space re-puncture.

2 ex

FIELD: medicine.

SUBSTANCE: two-duct drain tube is intraoperatively inserted into a residual cavity. The tube is delivered onto an anterior abdominal wall. The cyst cavity is irrigated with 0.05% chlorhexidine every day from the second postoperative day that is followed by administering the preparation of 10% povidone iodine with the drain tube pinched for 3-5 minutes. The procedure is performed until the cyst cavity is eliminated completely.

EFFECT: method provides the reliable treatment of the residual cyst cavity following marsupialisation and open echinococcectomy, as well as prevents the postoperative complications by achieving the aseptic inflammation of the inner surface of the fibrous capsule surface followed by the cyst cavity obliteration.

2 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and veterinary science, namely to a targeted drug delivery into a living body. The object of the presented invention is simplifying the process of the targeted drug delivery into the malignant new growth and increasing the local drug delivery into the tumour. The assigned object is achieved by administering drugs from the group of antitumour chemotherapeutic preparations fixed on a solid carrier into a patient's body by placing one or more drug containers immediately into the tumour tissue in blocks with a block volume related to its outer surface as 10-1500 mcm, consisting of a biocompatible porous base having a porosity of 40-75 vol. % pores of which comprise the drug in an amount of 1-100 mg in 1 cm3 of the porous base, while the number of the drug containers placed into the tumour is specified from the relation Vtum=(2-2000)·n·Vdc, wherein Vtum is the tumour volume, n is the number of the placed drug containers, Vdc is the drug container volume.

EFFECT: presented method provides the targeted drug delivery into the tumour tissues, thereby providing the tumour cell death that is necessary in treating tumour diseases; the method is simple and requires no complicated technical devices to be used.

5 cl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to intravaginal drug delivery system the above system (5) comprises at least one portion (1a and 1b), comprising an inner portion (2) with a cross-section diameter d2 equal to 2-10 mm, and a membrane (3) covering the inner portion, wherein the inner portion and the membrane substantially consist of the same polymer structure or various polymer structures. Besides, the intravaginal drug delivery system comprises a connector (6) permeable for a therapeutically active substances with the cross-section diameter d6 equal to 0.5-4.0mm for forming the continuous working drug delivery system. The present invention also refers to a method for making the above intravaginal drug delivery system.

EFFECT: invention provides the controlled release rate of the therapeutically active substances.

12 cl, 4 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to developing expandable medical devices, particularly stents, and can be used for treating restenosis in a vessel lumen. A presented implantable medical device involves intraluminal frame (IF) comprising a number of openings. The IF has a tubular configuration and comprises a number of cylindrical sections connected by the number of connective elements. Each of the cylindrical sections of the IF is formed of a mesh of elongated braces connected by plastic pivots and peripheral braces. Different openings of the IF are filled with at least two various therapeutic agents. At least one therapeutic agent filling one of the openings is incorporated into poly(lactic-co-glycolic acid) (PLGA) matrix to control a release rate and a cumulative released dose of the therapeutic agent into the surrounding tissue.

EFFECT: invention provides the effective combination therapy by using two or more drugs and/or active substances filling the different openings of the devices keeping its wall thickness the same with no limitation of its movement, as well as by enabling the drug delivery with various release kinetics and/or clearance period.

6 cl, 2 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and medical equipment, namely to obstetrics and gynaecology, and can be used for the local treatment of inflammatory diseases of the uterine cavity. The method is implemented by inserting a waveguide of a presented device in a protection enclosure into the uterine cavity. A taper base of a narrow portion of the enclosure leans on an external orifice of the cervical uterus to prevent accidental perforation of the uterus. An infusion system regulator is used to set the spray supply of a therapeutic solution into an irrigation canal of the ultrasonic device. Thereafter ultrasonic vibrations are generated, and the uterine cavity is treated with the sounded therapeutic solution. The exposure length is 3-5 minutes at the ultrasonic vibration frequency of 25 kHz, infusion rate approximately 100-150 ml/min. The total infusion volume is not less than 300 ml. The ultrasonic treatment enables providing the continuous outflow of the uterine discharge. The device comprises an US generator, an acoustic assembly, the waveguide with the protection enclosure, the infusion system for the therapeutic solution supply. The acoustic assembly and waveguide comprises the irrigation canal. A working tip of the waveguide represents a short cylinder having a diameter greater than the rest portion. The irrigation canal of the waveguide has a diameter of 2 mm. The protection metal thin-wall enclosure has a crimped distal end and drain holes and represents two cylindrical elements of various diameters connected by a taper junction with milled grooves arranged so that to enable the fluid access to the working tip cylinder, the length of which makes no more than 3 mm.

EFFECT: inventions provide the effective cleansing of the uterine cavity from infected and necrotised tissues with improved comfort and safety of the procedure with using no endoscopic equipment, cervical dilation manipulations and uterine pre-probing.

2 cl, 3 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medical equipment, namely to means of carrying out low-invasive surgical operations. A surgical ultrasonic instrument contains coordinating and conducting elements for the transmission of an ultrasonic signal and a working end connected to the conducting element. The conducting element and/or working end have at least one section with different physical and/or mechanical properties, obtained by performing its thermal and/or mechanical treatment or made from a material, different from the material of adjacent section(s). A device for the ablation of a pathological mass additionally contains a generator of ultrasonic fluctuations and an acoustic unit. The method of the pathological mass ablation from a biological tissue consists in the application of the device for the pathological mass ablation.

EFFECT: improvement of transmission of ultrasonic fluctuations, provision of sufficient dynamic stability of the ultrasonic instrument and control of the curvature of a trajectory of elastic deformation of the conducting element and working end of the ultrasonic instrument.

27 cl, 13 dwg

Reverse evaporator // 2532502

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to medical equipment. It can be used for surgeries and postoperative care of wounds (including injuries, burns, freezing injuries and trophic ulcers), as well as soft tissues and mucous membranes for bleeding control, prevention and treatment of suppurative complications, infectious and dermatologic diseases. The object of the presented device is providing the local, targeted haemostatic and/or antiseptic preparation of biological tissues with an ozone-oxygen mixture in a combination with the effective aspiration and deactivation of ozone from the used gas mixture, staying within the maximum permissible ambient ozone concentration. The assigned object is solved by the fact that the device additionally comprises a motor and storage portions combined together into a one-piece working circuit. A tip in the form of an ozone handle and peripheral aspiration and release pumps connected by a plastic retainer; pump inlets and outlets are presented in the form of junction pipes provided with conical nozzles with adapters, are parts of the motor portion. The storage portion comprises a chain of cross-pieces coupled in the same direction by supplying pipes and provided on each side from each cross-piece with a pair of hermetic ozone-oxygen packages on the opposite crossarms.

EFFECT: presented reverse evaporator enables avoiding sophisticated, bulky, immobile treatment apparatuses and using the aggressive gas media, like ozone-oxygen mixtures.

3 cl, 4 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medical equipment. Device contains cylindrical case element, plunger and cover, made with possibility f travel between closing position and dispensing position. Cover includes hole, which has specified dimensions to provide leaking of medication through cover, when cover is in dispensing position. Cylindrical case element has multitude of internal thread coils. Connection of cover and case is realised due to the fact that cover includes external wall and column, extending towards cylindrical case element, column includes external thread coils, or cylindrical case element includes multitude of external thread coils, and cover includes multitude of internal thread coils, which have such dimensions that they are capable of mating in thread coils of external thread of cylindrical case element, and/or cylindrical case element includes multitude of internal thread coils, and cover includes multitude of cogs, which have multitude of external thread coils, which have such dimensions that it is capable of mating in thread said coils of internal thread of cylindrical case element (12), or cylindrical case element includes flange part, passing from distal end, projection, formed near distal end, first groove and second groove, with cover including first holding bead, which has such dimensions that it is capable of interaction with flange part, and second holding bead, which has such dimensions that is capable of snapping shut in first groove, when cylindrical case element is in closing position, and has such dimensions that it is capable of snapping shut in second groove, when first holding bead interacts with flange part, in order to place cover in dispensing position. Device additionally contains holding means to hold cover on cylindrical case element, when cover is in dispensing position.

EFFECT: providing delivery of specified dose at any moment due to travel of case element between closing and dispensing position without separating cover from device.

13 cl, 14 dwg

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to gynaecology, and can be used in treating such diseases as dysfunctional uterine bleeding, menorrhagia, dysmenorrhoea, endometriosis, uterine fibroid, menopausal disorders, osteoporosis and urogenital atrophy. That is ensured by presenting an urogenital system comprising a frame forming an internal cavity enclosing an insert with a therapeutically effective dose of a biologically active compound. The insert is form-stable and damage-resistant when in use. The frame has an open structure providing access to a main portion of an external portion of the insert. The frame comprises one or more retaining element for frame holding in the uterine. What is also presented is a method for making the above intrauterine system.

EFFECT: group of inventions provides an effective controlled release drug delivery for a long period of time, as well as easy and safe administration and proper removal of the preparation.

14 cl, 9 dwg

FIELD: medicine.

SUBSTANCE: invention relates to field of medical equipment, in particular to devices for blood pumping. Pump contains elastic cylindrical case, restricted from butt ends with rigid partitions and connected to them in hermetic way, input and output holes, made with possibility of closing. Rigid cylindrical hollow case is hermetically closed on butt ends with plugs. Electronic control unit, provided with switchable power sources, is placed inside rigid cylindrical hollow case. Artificial muscles are connected with electronic control unit with possibility of contraction when control signals are emitted. Artificial muscles are built into envelope of elastic cylindrical case, are made in form of ring straps, ends of which converge with insulating space to bus for transmission of control signals and have possibility to contract wall of elastic case to press fluid out.

EFFECT: increased compactness of pump construction.

4 dwg

Up!